NEJM on supplements
This article was originally published in The Tan Sheet
"Manufacturers of dietary supplements should obtain premarketing approval from the FDA by demonstrating that their products present no substantial or unreasonable risk of injury," Donald Marcus, MD, Baylor College of Medicine, Houston, and Arthur Grollman, MD, SUNY Stony Brook, write in an editorial in the Dec. 19 NEJM. Authors also suggest supplement manufacturers "be required to report all adverse effects...to the FDA." Piece is one of three articles on botanical supplements that appear in the issue. In response, CRN says many of the authors' six suggestions "are already in progress...[or] can be accomplished by fully implementing" DSHEA. The same day, FDA unveiled a multi-pronged plan addressing regulation and enforcement of the supplement industry...
You may also be interested in...
When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.
Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.
COVID-19: String Of FDA Guidance Docs Lay Bare Enforcement Policies For Infusion Pumps, ECMO Devices, Thermometers, And More
In three separate immediately-in-effect guidance documents, the US agency says makers of infusion pumps and accessories, extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass devices, and remote ophthalmic assessment and monitoring devices can make “limited modifications” to those products so they can be used during the ongoing novel coronavirus crisis, without the need for firms to seek out a new 510(k). A fourth guidance says clinical electronic thermometers that aren’t yet 510(k)-cleared by the FDA can be distributed for use.